Acción SLDB SOLID BIOSCIENCES INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Solid Biosciences Inc.

Acciones

SLDB

US83422E2046

Tiempo real estimado Cboe BZX
Otros sitios de cotización
 20:51:08 26/06/2024 		Varia. Cinco días. Varia. 1 de enero.
5,6 USD -3,45 % Gráfico intradía de Solid Biosciences Inc. -9,68 % -7,33 %
21/06 Principales ganancias antes de la comercialización MT
11/06 Solid Biosciences Inc. anuncia su dimisión del Consejo de Administración CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Top Premarket Gainers
Solid Biosciences Inc. Announces Board Resignations
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
Solid Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label
Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
North American Morning Briefing : Inflation -2-
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
Solid Biosciences Inc. Announces Licensing Agreement with Armatus Bio for the Use of Aav-Slb101, A Proprietary, Muscle-Targeted Capsid, in the Development of an Rnai Therapy to Treat Fshd
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Gets FDA Orphan Drug Designation for Duchenne Drug Candidate
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción SLDB
  4. Noticias Solid Biosciences Inc.
  5. Otros idiomas